• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Malaysian Health Technology Assessment (MaHTAS) Tertiary care virtual online consultation between doctor and patient
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     NIHR Health Technology Assessment programme Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Neurophysiological facial nerve monitoring during parotid gland surgery]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Lutetium 177 PSMA in patients with prostate cancer]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2022     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Vagus nerve stimulation for drug-resistant epilepsy]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of adults with non-infectious uveitis
2022     Ontario Health Genetic testing for familial hypercholesterolemia
2022     NIHR Health Technology Assessment programme Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022     Ontario Health Pre-surgical nasal decolonization of staphylococcus aureus
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Sialendoscopy for obstructive salivary gland disease]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fecal microbiota transplantation for recurrent Clostridioides difficile infection]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Casirivimab and imdevimab to treat Covid-19 in patients negative for the Omicron genotype]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Onasemnogene abeparvovec (Zolgensma®) for spinal muscular atrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fluorodopa PET scanning in Parkinson’s disease]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Corneal collagen crosslinking with riboflavin in keratoconus]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Adjunctive colposcopy technologies (videocolposcopy) for cervical conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Prenatal cell-free DNA in maternal blood screening to assess chromosomal disorders in single pregnancy]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2022     NIHR Health Technology Assessment programme A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery in obese patients with gastroesophageal reflux and/or Barrett’s esophagus]
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Crizanlizumab for preventing sickle cell crises in sickle cell disease. NICE technology appraisal guidance 743
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Health Technology Wales (HTW) Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021     Health Information and Quality Authority (HIQA) Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021     NIHR Health Technology Assessment programme A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021     Belgian Health Care Knowledge Centre (KCE) Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021     Health Information and Quality Authority (HIQA) Use of respirator masks by persons who are at higher risk from COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     National Institute for Health and Care Excellence (NICE) NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021     Health Council of the Netherlands Gezondheidsraad (GR) [Influenza vaccination: review of indications]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways: a systematic review
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (primary chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     WorkSafeBC Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021     National Institute for Health and Care Excellence (NICE) Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021     Center for Drug Evaluation (CDE) Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sodium zirconium cyclosilicate (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021     WorkSafeBC Acupuncture or massage therapy as treatment for occipital neuralgia
2021     National Institute for Health and Care Excellence (NICE) Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Percutaneous repair systems for tricuspid valve insufficiency by annuloplasty]
2021     Adelaide Health Technology Assessment (AHTA) Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021     Center for Drug Evaluation (CDE) Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021     Health Technology Wales (HTW) Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021     Adelaide Health Technology Assessment (AHTA) Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021     NIHR Health Technology Assessment programme Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021     Adelaide Health Technology Assessment (AHTA) Genomic testing for the diagnosis of heritable cardiomyopathies
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bedaquiline (multidrug resistant tuberculosis: children aged 5 to 11 years) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     National Institute for Health and Care Excellence (NICE) Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751
2021     Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for TAVI]
2021     National Institute for Health and Care Excellence (NICE) Belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE technology appraisal guidance 752
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial nutrition in acute pancreatitis]
2021     National Institute for Health and Care Excellence (NICE) Cenobamate for treating focal onset seizures in epilepsy. NICE technology appraisal guidance 753
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: initial tube feeding in acute pancreatitis]
2021     National Institute for Health and Care Excellence (NICE) Mogamulizumab for previously treated mycosis fungoides and Sezary syndrome. NICE technology appraisal guidance 754
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]